A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
3.
CANCER INTERVENTION BY TARGETING GENOTYPIC DIFFERENCES USING CRISPR-CAS3 MEDIATED DELETION-EDITING
Provided are compositions and methods for selectively killing cancer cells. The method includes obtaining one or more biological samples from an individual, determining different nucleotide sequences in cancer and non-cancer cells from the biological sample using an algorithm to identify a candidate target sequence that is present in the cancer cells and not present in the non-cancer cells. Based on the different nucleotide sequences in the cancer cells relative to the non-cancer cells a CRISPR Cas3 system that includes a guide RNA targeted to an identified segment of the chromosome that is linked to the target sequence is degraded.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G16B 30/10 - Alignement de séquenceRecherche d’homologie
4.
SEQUENTIAL TREATMENT METHOD FOR P53-DEFICIENT CANCER
Disclosed is a method of treating or alleviating a symptom of a cancer in a subject, comprising sequentially administering to the subject a combination of a thymidine analogue and a PARP inhibitor, followed by administration of a G2-kinase inhibiting drug.
A61K 31/5025 - PyridazinesPyridazines hydrogénées condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/7072 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique ayant deux groupes oxo liés directement au cycle pyrimidine, p. ex. uridine, acide uridylique, thymidine, zidovudine
Provided is an immunogenic composition including a peptide, wherein consecutive amino acids of the peptide include at least amino acids of SEQ ID NO:1 and one or more adjuvant. Also provided is a method of vaccinating a subject against Borrelia burgdorferi, including administering to the subject an effective amount of the immunogenic composition
Provided are methods for treating cancer. The methods involve administering to an individual who has cancer a combination of peptidase D (PEPD), a sheddase inhibitor, a chemotherapeutic agent and a coagulation inhibitor.
Provided is method of detecting SARS-CoV-2 in a sample, including amplifying polynucleotides in the sample to form subgenomic amplicons using a forward subgenomic primer and a reverse subgenomic primer, wherein the forward subgenomic primer hybridizes to a forward subgenomic primer target of a subgenomic SARS-CoV-2 N protein transcript or its complement and the reverse subgenomic primer hybridizes to a reverse subgenomic primer target of the subgenomic SARS-CoV-2 transcript or its complement, and detecting an amount of hybridization of a subgenomic SARS-CoV-2 transcript probe to the subgenomic amplicons, wherein the subgenomic SARS-CoV-2 transcript probe hybridizes to a probe target of the subgenomic amplicons, wherein the probe target of the subgenomic amplicons includes at least a portion of a leader sequence, a transcriptional regulatory sequence, and at least a portion of a junction region between the transcriptional regulatory sequence and a coding sequence of the subgenomic SARS-CoV-2 transcript and the probe target is between the forward subgenomic primer target and the reverse subgenomic primer target
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
C12Q 1/686 - Réaction en chaine par polymérase [PCR]
8.
FOLATE RECEPTOR ALPHA -TARGETING BI-SPECIFIC T CELL ENGAGERS (BiTEs) AND USES THEREOF
Provided are modified cells and methods for their use in treating cancer. The cells are modified to express and secrete a Bi-specific T cell engager (BiTE) that includes a segment that specifically binds to human Folate Receptor alpha (FRα) and a segment that that specifically binds to human CD3, such as CD3e. The modified cells can be T cells. Methods for producing the modified cells are also provided.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
Provided is a method for treating an individual for a programmed-death 1 (PD-1) immune checkpoint therapy resistant cancer. The method involves administering to the individual a combination of a Toll-like receptor 3 (TLR3) agonist and interferon-alpha (IFNα), followed by close in time administration of an anti-PD-1 immunotherapy.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
10.
METHOD OF MITIGATION OF INJURIES CAUSED BY SYSTEMIC GENOTOXIC STRESS
Provided are methods for therapy or prophylaxis of genotoxic stress. The methods include administering to an individual in need an effective amount of Matrix Metalloproteinase (MMP)-9. The individual in need may have or be at risk of developing Acute Radiation Syndrome (ARS), or may have received or is receiving chemotherapy, or has insufficient hematopoietic function. The present disclosure provides results from a mouse model of lethal ARS induced by TBI to demonstrate that neutrophils (N) are essential mediators of the radiomitigative but not radioprotective abilities of entolimod, express functional TLR5 butundergo minimal transcriptional changes post-entolimod suggesting that N mitigate 30 ARS through a transcriptional-independent mechanism; and increase the number of active hematopoietic B pluripotent precursors (HPPs) in bone marrow.
Disclosed is a method of treating or alleviating a symptom of a cancer in a subject, comprising sequentially administering to the subject TAS-102 followed by a BCL-2 inhibitor.
Provided are methods for treatment of survivin-positive autoimmune diseases comprising administration of survivin specific antibodies to subjects who are afflicted with an autoimmune disease.
H. Lee Moffitt Cancer Center and Research Institute, Inc. (USA)
Inventeur(s)
Kalinski, Pawel
Czerniecki, Brian
Abrégé
Provided are compositions and methods for prophylaxis or therapy of cancer. The compositions comprise α-type-1 dendritic cells that have been treated with intact proteins that comprise cancer antigens, or peptides that comprise cancer antigens, or combinations thereof. The approaches can also include adding a chemokine-modulating regimen.
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Provided are compositions and methods for prophylaxis and/or therapy of ErbB2-positive cancer. The compositions include pharmaceutical preparations that contain isolated or recombinant or modified peptidase D (PEPD) proteins. The methods include prophylaxis and/or therapy of ErbB2-positive cancer by administering a PEPD to an individual who has or is at risk for developing ErbB2-positive cancer.
The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents (such as tyrosine kinase inhibitors or VEGF/VEGFR inhibitors), particularly anticancer agents such as sunitinib, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
A61K 31/4412 - Pyridines non condenséesLeurs dérivés hydrogénés ayant des groupes oxo liés directement à l'hétérocycle
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A device includes a first fiber lock configured to be attached to a handle of an EUS-NA device and to selectively lock or unlock a fiber optic cable in position with respect to a sample needle. A second fiber lock is configured to be attached to abase of the EUS-NA device and to selectively lock or unlock a fiber optic cable in position. A method includes passing a fiber optic cable through a passage of the EUS-NA device such that an end of the fiber optic cable is at a tip of a sample needle of the EUS-NA device. The fiber optic cable is locked relative to the sample needle, and the sample need is advanced into the target tissue. The fiber optic cable is unlocked from the sample needle and locked relative to abase of the EUS-NA device. The sample needle is retracted such that the end of the fiber optic cable remains in the target tissue.
Provided are compositions and methods that relate to therapy of B cell diseases and include discovery of novel molecular heterogeneity of the signaling component (i.e., CD79) of human B cell antigen receptor (BCR). The method includes co-administering antibodies or antigen binding fragments thereof that specifically bind CD79a and CD79b to provide synergistic therapy of B cell tumors. The method may further include administering an antibody that specifically binds to an immune checkpoint molecule, such as programmed cell death protein 1 (PD-1).
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
19.
ANTIPROLIFERATIVE BETTI BASES AND PRODRUGS THEREOF
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
HEALTH RESEARCH, INC. (USA)
Inventeur(s)
Wang, Xinjiang
Chemler, Sherry R.
Lama, Rati
Galster, Samuel
Abrégé
Provided are compounds with the structure: Also provided are compositions of the compound. The compounds have broad anti¬ proliferative activity against cancer cells, including leukemia, pancreatic cancer, and melanomas. Also provided are methods for inhibiting the growth of cells and/or inducing apoptosis and/or ferroptosis.
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
A61K 31/4402 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 2, p. ex. phéniramine, bisacodyl
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
C07D 213/16 - Composés hétérocycliques contenant des cycles à six chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle et avec au moins trois doubles liaisons entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques comportant trois liaisons doubles ne comportant pas de liaison entre l'atome d'azote du cycle et un chaînon non cyclique ou ne comportant que des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle contenant uniquement des atomes d'hydrogène et de carbone en plus de l'atome d'azote du cycle ne contenant qu'un cycle pyridique
C07D 215/12 - Composés hétérocycliques contenant les systèmes cycliques de la quinoléine ou de la quinoléine hydrogénée ne comportant pas de liaison entre l'atome d'azote du cycle et un chaînon non cyclique ou ne comportant que des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle avec des radicaux hydrocarbonés substitués liés aux atomes de carbone du cycle
C07D 215/28 - AlcoolsLeurs éthers avec les atomes d'halogènes ou les radicaux nitro en positions 5, 6 ou 7
Antibody derivatives are provided as binding partners. The binding partners bind to a one or a combination of antigens that include antigens present CD24, CD105 (endoglin), CD79 Beta (CD79b), and an antigen present in a CD3 T cell co-receptor. The antibody derivatives include single chain variable fragments (scFvs), Bi-specific T-cell engagers (BiTEs). Also provided are modified cells that express the binding partners, modified cells that secrete the binding partners, expression vectors that encode the binding partners, and methods of using the binding partners for treatment of a variety of cancers, autoimmune diseases, and modification of immune responses mounted to transplanted organs.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
A method for treating cancer is provided. The method includes administering a combination of a Prolidase, also known as peptidase D (PEPD), in combination with a monoclonal antibody or antigen binding fragment thereof that binds with specificity to a clotting factor, such as Factor XII (FXII). A single dose of the monoclonal antibody is sufficient to enable a therapeutic effect of the PEPD.
A61K 38/00 - Préparations médicinales contenant des peptides
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
22.
LOCK TO POLE BIOMETRIC ACCESS INTRAVENEOUS MEDICATION LOCKBOX
A container is provided for securing IV medication during use. The container includes a housing with a removable cover. The housing has an internal volume for placement of IV medication. In other words, the housing and the cover form an internal volume when the container is closed. The container has a biometric lock for selectively locking the cover to the housing. The biometric lock may be a fingerprint lock. The biometric lock may be configured to store an access log. In another aspect, a method for securing IV medication during use is provided.
Provided are methods for prophylaxis and therapy for viral infections. The methods can facilitate a synergistic anti-viral effect. The method involves administering a combination of agents to an individual in need thereof. The combinations of agents are selected from interferons (IFNs), Toll-Like Receptor (TLR) ligands, polyinosinic:polycytidylic acid, rintatolimod, tumor necrosis factor alpha (TNF-a) or an inducer thereof, and nuclear factor kappa B (NF-xB) or an inducer or activator thereof.
The present disclosure relates to a fluid treatment apparatus. The fluid treatment apparatus includes a first system for removing one or more target compounds from a fluid, said first system comprising adsorbent particles; a second system for regenerating said adsorbent particles; a first connector between said first system and said second system, said first connector configured to transfer adsorbent particles from said first system to said second system; and a second connector between said first system and said second system, said second connector configured to release of adsorbent particles from said second system, wherein said first system and said second system are decoupled. The present disclosure further relates to a system comprising one or more fluid treatment apparatus described herein. Also described herein are methods for treating fluid and a system comprising the methods for treating fluid described herein.
B01D 15/02 - Procédés de séparation comportant le traitement de liquides par des adsorbants ou des absorbants solidesAppareillages pour ces procédés par des adsorbants en mouvement
B01D 15/20 - Adsorption sélective, p. ex. chromatographie caractérisée par des caractéristiques de structure ou de fonctionnement relatives au conditionnement de la matière adsorbante ou absorbante
C02F 1/28 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par absorption ou adsorption
C02F 1/32 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par irradiation par la lumière ultraviolette
C02F 1/36 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout au moyen d'oscillations mécaniques par des vibrations ultrasonores
B01J 20/08 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant des oxydes ou des hydroxydes des métaux non prévus dans le groupe contenant de l'oxyde ou de l'hydroxyde d'aluminiumCompositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant des oxydes ou des hydroxydes des métaux non prévus dans le groupe contenant de la bauxite
B01J 20/10 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant de la silice ou un silicate
B01J 20/20 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant du carbone libreCompositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant du carbone obtenu par des procédés de carbonisation
C02F 1/70 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par réduction
The present disclosure provides methods for treating an individual in need of a composition having a compound having the following structure: Formula (I) The methods may be used to disrupt mitochondrial unfolded protein response. In various examples, a compound of the composition binds to heat shock protein 60 (HSP60) and inhibits the interaction of HSP60 to ClpP, thus interrupting the mitochondrial unfolded protein response. For example, the composition may be used as a therapeutic approach for treating advanced prostate cancers that are no longer sensitive to AR targeted therapies.
The present disclosure provides methods for treating an individual in need of a composition having a compound having the following structure: Formula (I) The methods may be used to disrupt mitochondrial unfolded protein response. In various examples, a compound of the composition binds to heat shock protein 60 (HSP60) and inhibits the interaction of HSP60 to ClpP, thus interrupting the mitochondrial unfolded protein response. For example, the composition may be used as a therapeutic approach for treating advanced prostate cancers that are no longer sensitive to AR targeted therapies.
Provided are compounds and compositions that inhibit glucose-induced growth signaling and methods of using same. The compounds may be suitable to treat glycolytic cancers, such as, for example, esophageal squamous cell carcinoma (ESCC). The compounds may be used to inhibit or partially inhibit glucose-promoted tumor cell proliferation, NME-1 catalyzed histidine phosphorylation of FAK, and FAK interaction with RBI. The compounds may have the following structure:
Provided are compounds and compositions that inhibit glucose-induced growth signaling and methods of using same. The compounds may be suitable to treat glycolytic cancers, such as, for example, esophageal squamous cell carcinoma (ESCC). The compounds may be used to inhibit or partially inhibit glucose-promoted tumor cell proliferation, NME-1 catalyzed histidine phosphorylation of FAK, and FAK interaction with RBI. The compounds may have the following structure:
C07D 253/07 - Triazines-1, 2, 4 comportant trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des hétéro-atomes ou des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
C07C 233/81 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des groupes carboxyle
C07D 271/113 - Oxadiazoles-1, 3, 4Oxadiazoles-1, 3, 4 hydrogénés avec des atomes d'oxygène, de soufre ou d'azote, liés directement aux atomes de carbone du cycle, les atomes d'azote ne faisant pas partie d'un radical nitro
C07D 239/74 - QuinazolinesQuinazolines hydrogénées avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés aux atomes de carbone de l'hétéro-cycle
C07D 209/42 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
C07D 307/93 - Composés hétérocycliques contenant des cycles à cinq chaînons comportant un atome d'oxygène comme unique hétéro-atome du cycle condensés en ortho ou en péri avec des carbocycles ou avec des systèmes carbocycliques condensés avec un cycle autre qu'un cycle à six chaînons
C07D 239/70 - Composés hétérocycliques contenant des cycles diazine-1, 3 ou diazine-1, 3 hydrogéné condensés avec des carbocycles ou avec des systèmes carbocycliques
C07C 49/643 - Composés non saturés comportant un groupe cétone faisant partie d'un cycle polycycliques le groupe cétone faisant partie d'un système cyclique condensé comportant trois cycles
C07D 257/02 - Composés hétérocycliques contenant des cycles comportant quatre atomes d'azote comme uniques hétéro-atomes du cycle non condensés avec d'autres cycles
C07D 311/20 - Benzo [b] pyrannes non hydrogénés dans le carbocycle avec des atomes d'oxygène ou de soufre liés directement en position 2 hydrogénés dans l'hétérocycle
C07C 281/08 - Composés contenant l'un des groupes p. ex. semicarbazides l'autre atome d'azote étant lié de plus par une liaison double à un atome de carbone, p. ex. semicarbazones
C07D 327/08 - Cycles à six chaînons condensés en [b, e] avec deux carbocycles à six chaînons
A61K 31/53 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec trois azote comme seuls hétéro-atomes d'un cycle, p. ex. chlorazanil, mélamine
A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
A61K 31/122 - Cétones ayant l'atome d'oxygène lié directement à un cycle, p. ex. quinones, vitamine K1, anthraline
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 31/4748 - QuinoléinesIsoquinoléines formant une partie de systèmes cycliques pontés
A61K 31/175 - Amides, p. ex. acides hydroxamiques ayant le groupe N-C(O)-N ou N-C(S)-N, p. ex. urée, thiourée, carmustine ayant le groupe , N-C(O)-N=N- ou , p. ex. carbonohydrazides, carbazones, semicarbazides, semicarbazonesLeurs thio-analogues
A61K 31/382 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à six chaînons, p. ex. thioxanthènes
27.
METHODS FOR TREATING PANCREATIC DUCTAL ADENOCARCINOMA
Provided are methods for treating individuals suspected of having or having Cleavage and Polyadenylation Specificity Factor 3 (CPSF3) associated cancer via administration of a CPSF3 inhibitor. Such cancers include pancreatic ductal adenocarcinoma (PDAC). The CPSF3 inhibitor may further attenuate PDAC cell proliferation and colony formation. The CPSF3 inhibitor may be JTE-607, which has the following structure:
Provided are methods for treating individuals suspected of having or having Cleavage and Polyadenylation Specificity Factor 3 (CPSF3) associated cancer via administration of a CPSF3 inhibitor. Such cancers include pancreatic ductal adenocarcinoma (PDAC). The CPSF3 inhibitor may further attenuate PDAC cell proliferation and colony formation. The CPSF3 inhibitor may be JTE-607, which has the following structure:
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
28.
METHODS AND SYSTEMS FOR OPTIMIZING VOLUMETRIC MODULATED ARC THERAPY (VMAT) TREATMENT PLANS
A volumetric modulated arc therapy (VMAT) treatment plan may be optimized by obtaining a VMAT treatment plan and calculating a radiation dose matrix corresponding to each a plurality of beamlets, wherein each beamlet represents a change in field when an MLC leaf is moved a predetermined unit distance. The method includes defining an enhanced objective function (EOF) for achieving one or more clinical objectives and minimizing the EOF for proposed leaf positions iterating through each leaf of at least a subset of the leaves of the VMAT treatment plan (wherein the proposed leaf positions move each leaf into the field or out of the field by the predetermined unit distance and correspond to the addition or subtraction of the corresponding radiation dose matrix). The set of leaf positions of the VMAT treatment plan is updated according to the proposed leaf positions of the minimized EOF.
Provided are modified cells and methods for their use in treating cancer. The cells are modified to express and secrete a Bi-specific T cell engager (BiTE) that includes a segment that specifically binds to human Folate Receptor alpha (FRα) and a segment that that specifically binds to human CD3, such as CD3e. The modified cells can be T cells. Methods for producing the modified cells are also provided.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
The Board of Regents of the University of Texas System (USA)
Inventeur(s)
Li, Hongmin
Li, Zhong
Zhou, Jia
Xu, Jimin
Abrégé
The present disclosure relates to a Prp8 intein splicing inhibitor. The present disclosure further relates to a method of treating and/or preventing a fungal infection, said method comprising administering a Prp8 intein splicing inhibitor under conditions effective to treat and/or prevent a fungal infection. Also disclosed is a method of inhibiting Prp8 intein expression or activity in a cell or tissue, said method comprising administering a compound under conditions effective to inhibit Prp8 intein expression or activity in a cell or tissue. Further disclosed are methods for screening for compounds that inhibit Prp8 intein splicing comprising an assay and a kit for predicting the likelihood of Prp8 inhibition.
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
Provided are methods and compositions for the treatment of cancer. The methods comprise administering to an individual in need of treatment inhibitors of WHSC1 expression, function or activity in combination with PARP inhibitors or immune based therapy. In an aspect, the present disclosure provides compositions comprising one or more WHSC1 inhibitors and one or more PARP inhibitors, or one or more WHSC1 inhibitors and one or more immune checkpoint inhibitors.
A device for automatic suturing includes a shaft having a longitudinal axis. The shaft has a joint rotatable about a joint axis which is at an angle>0° to the longitudinal axis. The device includes a clamp at a distal end of the shaft. The clamp is configured to be positioned over a length of tissue to be sutured. A driver is configured to engage with a screw of the shaft so that the driver translates along a length of the shaft when the driver is rotated. A helical needle is connected to the driver such that rotation of the driver causes rotation of the helical needle. In this way, the needle is advanced or retracted over a length of the clamp and over the joint of the shaft.
A61B 17/04 - Instruments, dispositifs ou procédés chirurgicaux pour refermer les plaies ou les maintenir ferméesAccessoires utilisés en liaison avec ces opérations pour la suture des plaiesSupports ou emballages pour aiguilles ou matériaux de suture
33.
CANCER INTERVENTION BY TARGETING GENOTYPIC DIFFERENCES USING CRISPR-CAS3 MEDIATED DELETION-EDITING
Provided are compositions and methods for selectively killing cancer cells. The method includes obtaining one or more biological samples from an individual, determining different nucleotide sequences in cancer and non-cancer cells from the biological sample using an algorithm to identify a candidate target sequence that is present in the cancer cells and not present in the non-cancer cells. Based on the different nucleotide sequences in the cancer cells relative to the non-cancer cells a CRISPR Cas3 system that includes a guide RNA targeted to an identified segment of the chromosome that is linked to the target sequence is degraded.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
The present disclosure provides a method and a system for treating a tissue using photodynamic therapy (PDT). A photosensitizer is administered to the tissue and one or more optical fibers are placed in the tissue. A treatment light is applied to the tissue by way of the one or more optical fibers. A temperature of the tissue is measured during application of the treatment light, and a fluence rate of the treatment light is modified based on the temperature of the tissue. For example, the fluence rate may be modified to be lower if the temperature of the tissue is higher than a predetermined threshold.
A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
G01K 7/36 - Mesure de la température basée sur l'utilisation d'éléments électriques ou magnétiques directement sensibles à la chaleur utilisant des éléments magnétiques, p. ex. des aimants, des bobines
35.
DEPLETING EGFR AND HER2 OVERCOMES RESISTANCE TO EGFR INHIBITORS IN COLORECTAL CANCER
Provided are methods for treating cancer. The methods involve administering to an individual who has cancer a combination of peptidase D (PEPD), a sheddase inhibitor, a chemotherapeutic agent and a coagulation inhibitor.
A61K 31/7115 - Acides nucléiques ou oligonucléotides ayant des bases modifiées, c.-à-d. autres que l'adénine, la guanine, la cytosine, l'uracile ou la thymine
A61K 31/737 - Polysaccharides sulfatés, p. ex. sulfate de chondroïtine, sulfate de dermatane
36.
METHODS RELATED TO BRONCHIAL PREMALIGNANT LESION SEVERITY AND PROGRESSION
The technology described herein is directed to methods of treating and diagnosing bronchial premalignant lesions, e.g. by determining the lesion subtype using one or more biomarkers described herein.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
37.
COMPOSITIONS AND METHODS FOR USE OF RECOMBINANT T CELL RECEPTORS AGAINST CLAUDIN 6
Provided are compositions and methods for prophylaxis and/or therapy of a variety of cancers which express a Claudin 6 (CLDN6) antigen. Included are recombinant T cell receptors (TCRs), polynucleotides encoding them, expression vectors that include the polynucleotides, and cells into which the polynucleotides have been introduced to produce modified cells, including CD4+ T cells, CD8+ T cells, and progenitor cells, such as hematopoietic stem cells. The modified cells are capable of direct and indirect recognition of a cancer ell expressing a CLDN6 antigen by human leukocyte antigen (HLA) class I and II restricted binding of the TCR to the CLDN6 antigen expressed by the cancer cell, with or without presentation of the antigen by antigen presenting cells. Also included is a method for prophylaxis and/or therapy of cancer by administering modified cells that express a recombinant TCR that binds to CLDN6.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
C12N 15/02 - Préparation de cellules hybrides par fusion de plusieurs cellules, p. ex. fusion de protoplastes
A61K 38/00 - Préparations médicinales contenant des peptides
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
38.
PHARMACEUTICAL COMPOSITIONS WITH ANTIFLAVIVIRAL ACTIVITY
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (USA)
Inventeur(s)
Li, Hongmin
Kramer, Laura D.
Li, Zhong
Huang, Ruili
Xia, Menghang
Abrégé
Provided is a method of inhibiting viral replication, including contacting one or more cells that has been infected or contacted with a flavivirus with an effective amount of niclosamide, temoporfin, nitazoxanide, tizoxanide, erythrosin B, methylene blue. Contacting one or more cells that have been infected with a flavivirus may include administering the compound to a mammal, a human, or other subject. The flavivirus may be Dengue virus serotype 1, Dengue virus serotype 2, Dengue virus serotype 3, Dengue virus serotype 4, yellow fever virus, West Nile virus, Zika virus, Japanese encephalitis virus, tick-born encephalitis virus, Powassan virus, St. Louis encephalitis virus, or other flavivirus.
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
C07C 235/64 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone de cycles aromatiques à six chaînons et des atomes d'oxygène, liés par des liaisons simples, liés au même squelette carboné avec des atomes de carbone de groupes carboxamide et des atomes d'oxygène, liés par des liaisons simples, liés à des atomes de carbone du même cycle aromatique à six chaînons non condensé avec des atomes de carbone de groupes carboxamide et des atomes d'oxygène, liés par des liaisons simples, liés en position ortho à des atomes de carbone du même cycle aromatique à six chaînons non condensé ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un cycle aromatique à six chaînons
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 31/409 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil ayant quatre de ces cycles, p. ex. dérivés de la porphine, bilirubine, biliverdine
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61P 31/14 - Antiviraux pour le traitement des virus ARN
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
DUKE UNIVERSITY (USA)
Inventeur(s)
Vare, Ville
Mcdonough, Kathleen
Schneider, Ryan
Agris, Paul
Seyler, Thorsten
Abrégé
Provided is a method for inhibiting the growth of Gram-positive bacteria, including contacting said bacteria with a first compound and a second compound, wherein the first compound is a compound of Formula I:
and the second compound is an antibiotic other than a compound of Formula I. Also provided is a composition including the first compound and the second compound.
A61K 8/49 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des composés hétérocycliques
A61Q 17/00 - Préparations protectricesPréparations employées en contact direct avec la peau pour protéger des influences extérieures, p. ex. des rayons du soleil, des rayons X ou d'autres rayons nuisibles, des matériaux corrosifs, des bactéries ou des piqûres d'insectes
A61K 31/7036 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine ayant au moins un groupe amino lié directement au carbocycle, p. ex. streptomycine, gentamycine, amikacine, validamycine, fortimicines
A01N 43/90 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant plusieurs hétérocycles déterminants condensés entre eux ou avec un système carbocyclique commun
A01P 1/00 - DésinfectantsComposés antimicrobiens ou leurs mélanges
Provided are methods for therapy or prophylaxis of genotoxic stress. The methods include administering to an individual in need an effective amount of Matrix Metalloproteinase (MMP)-9. The individual in need may have or be at risk of developing Acute Radiation Syndrome (ARS), or may have received or is receiving chemotherapy, or has insufficient hematopoietic function. The present disclosure provides results from a mouse model of lethal ARS induced by TBI to demonstrate that neutrophils (N ) are essential mediators of the radiomitigative but not radioprotective abilities of entolimod, express functional TLR5 but undergo minimal transcriptional changes post-entolimod suggesting that N mitigate 30 ARS through a transcriptional-independent mechanism; and increase the number of active hematopoietic pluripotent precursors (HPPs) in bone marrow.
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
41.
CANCER THERAPIES COMPRISING PEPTIDE LOADED CXCR3- AND CCR5-INDUCING DENDRITIC CELLS AND CHEMOKINE MODULATORY AGENTS
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (USA)
Inventeur(s)
Kalinski, Pawel
Czerniecki, Brian
Abrégé
Provided are compositions and methods for prophylaxis or therapy of cancer. The compositions comprise α-type-1 dendritic cells that have been treated with intact proteins that comprise cancer antigens, or peptides that comprise cancer antigens, or combinations thereof. The approaches can also include adding a chemokine-modulating regimen.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
Provided are methods for treatment of cancer. The method comprises administering to an individual who has cancer a combination of treatment to reduce MDSC burden and immune therapy. For example, an individual may be administered brequinar and an immune checkpoint inhibitor. This disclosure provides a method for redirecting early myeloid precursors away from generating MDSCs thereby reducing MDSC burden.
A61K 31/4353 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques
43.
REACTIVATING P53 MUTANTS FOR CANCER TREATMENT BY TARGETING PROLIDASE (PEPD)
Provided are methods for prophylaxis or therapy of cancer. The methods are directed to cancers that are characterized by expression of a mutant p53. The mutant p53 may be a loss of function p53 mutant, dominant negative p53 mutant, or a gain of function p53 mutant. The method comprises delivering to cancer cells an agent that can inhibit expression of prolidase (PEPD) or disrupts the association of mutant p53 with PEPD.
A device includes a first fiber lock configured to be attached to a handle of an EUS-NA device and to selectively lock or unlock a fiber optic cable in position with respect to a sample needle. A second fiber lock is configured to be attached to a base of the EUS-NA device and to selectively lock or unlock a fiber optic cable in position. A method includes passing a fiber optic cable through a passage of the EUS-NA device such that an end of the fiber optic cable is at a tip of a sample needle of the EUS-NA device. The fiber optic cable is locked relative to the sample needle, and the sample need is advanced into the target tissue. The fiber optic cable is unlocked from the sample needle and locked relative to a base of the EUS-NA device. The sample needle is retracted such that the end of the fiber optic cable remains in the target tissue.
A61B 18/18 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci par application de radiations électromagnétiques, p. ex. de micro-ondes
In some embodiments, an apparatus for implantable therapy includes a power supply and a first implantable component. The power supply includes a transmitter configured to provide a first signal at a first frequency. The power supply also includes a receiver configured to receive a second signal at a harmonic of the first frequency. The first implantable component includes an LC circuit configured to resonate at the first frequency. One or more light-emitting diodes (LEDs) of the first implantable component are configured to be powered by the first signal received at the LC circuit. In this way, powering the one or more LEDs forms a harmonic of the first signal (e.g., a third harmonic of the first signal). In some embodiments, the apparatus include a second implantable component with a sensor, which may be a light sensor.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
H02J 50/20 - Circuits ou systèmes pour l'alimentation ou la distribution sans fil d'énergie électrique utilisant des micro-ondes ou des ondes radio fréquence
Antibody derivatives are provided as binding partners. The binding partners bind to a one or a combination of antigens that include antigens present CD24, CD105 (endoglin), CD79 Beta (CD79b), and an antigen present in a CD3 T cell co-receptor. The antibody derivatives include single chain variable fragments (scFvs), Bi-specific T-cell engagers (BiTEs). Also provided are modified cells that express the binding partners, modified cells that secrete the binding partners, expression vectors that encode the binding partners, and methods of using the binding partners for treatment of a variety of cancers, autoimmune diseases, and modification of immune responses mounted to transplanted organs.
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
Provided are compositions, methods, and devices for reducing scarring during healing of a tissue wound. The compositions and methods involve use of sphingosine-1-phosphate (S1P), and/or an expression vector that encodes sphingosine kinase1 (SphK1). The compositions can be combined with other agents and implements, such as biocompatible nanoparticles, and medical devices involved with promoting wound healing. The approaches can reduce formation or prevent the occurrence of keloids.
A61K 31/661 - Acides du phosphore ou leurs esters n'ayant pas de liaison P-C, p. ex. fosfosal, dichlorvos, malathion
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
The present disclosure relates to a method for assessing color vision. The method includes identifying one or more steady-state visual evoked potentials (SSVEPs) to identify metamers. The present disclosure further relates to devices for assessing color vision that use metamers identified via steady-state visual evoked potentials (SSVEPs). Also disclosed herein are methods of treating color vision deficiency, systems for identifying a response to one or more metameric stimuli, methods of individually modifying color vision, methods for assessing color vision using neural activity as a means to personalize visual displays, and methods for assessing light sensitive cells in the nervous system using flashing lights.
A61B 3/06 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure subjective, c.-à-d. appareils de d’examen nécessitant la participation active du patient pour examen de sensibilité à la lumière, p. ex. d'adaptationAppareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure subjective, c.-à-d. appareils de d’examen nécessitant la participation active du patient pour examen de vision des couleurs
A61B 3/00 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux
Provided are methods and formulations for the treatment of p53-deficient cancers using a combinational drug strategy which enhances DNA damage in p53 deficient cells while not allowing cells to escape cell death by activation of p53-p21 signaling. Wild-type p53 carriers, on the other hand, respond with activation of p53-p21 signaling and cell-cycle arrest, thereby escaping cell death. The methods involve administering to an individual in need of treatment a combination of one or more poly (ADP ribose) polymerase inhibitors (PARPi) and one or more deoxyuridine analogs. Pharmaceutical formulations comprising PARPi and dU analogs are also provided.
A61K 31/7072 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique ayant deux groupes oxo liés directement au cycle pyrimidine, p. ex. uridine, acide uridylique, thymidine, zidovudine
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
A61K 31/5025 - PyridazinesPyridazines hydrogénées condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/502 - PyridazinesPyridazines hydrogénées condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. cinnoline, phtalazine
Provided are androstane and dihydrotestosterone compounds functionalized with carbocyclic groups or heterocyclic groups that may be saturated or unsaturated. The compounds may be used in methods of inhibiting cell growth of malignant cells and/or hyperplastic cells and/or treating individuals having diseases associated with malignant cell growth (e.g., cancer, such as, for example, prostate cancer) and/or hyperplastic cell growth and/or molecular imaging of malignant cells and/or hyperplastic cells and/or inducing degradation of a target protein. Also provided are compositions.
A61K 31/585 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine contenant des cycles lactone, p. ex. oxandrolone, bufaline
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/277 - NitrilesIsonitriles ayant un cycle, p. ex. vérapamil
A61K 31/4155 - 1,2-Diazoles non condensés et contenant d'autres hétérocycles
A61K 31/4166 - 1,3-Diazoles ayant des groupes oxo liés directement à l'hétérocycle, p. ex. phénytoïne
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
C07J 43/00 - Stéroïdes normaux ayant un hétérocycle contenant de l'azote non condensé ou condensé en spiro avec le squelette du cyclopenta[a]hydrophénanthrène
52.
ANTI-SURVIVIN ANTIBODIES FOR TREATMENT OF AUTOIMMUNE DISEASES
Provided are methods for treatment of survivin-positive autoimmune diseases comprising administration of survivin specific antibodies to subjects who are afflicted with an autoimmune disease.
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
53.
TETRAPYRROLIC CONJUGATES AND USES THEREOF FOR IMAGING
The Research Foundation for The State University of New York (USA)
Inventeur(s)
Pandey, Ravindra K.
Dukh, Mykhaylo
Marko, Aimee
Sajjad, Munawwar
Abrégé
Compounds for tumor imaging (e g , magnetic resonance (MR) and fluorescence) that may be used in combination with other methods to treat an individual having or suspected of having cancer (e.g., various forms of cancer, such as, for example, solid tumors). Compounds may have the following structure: (I) or a salt, a partial salt, a hydrate, a polymorph, an isomer (e.g., a structural or stereoisomer), or a mixture thereof, where R′ is an aryl group or heteroaryl group having a halogen group (e.g., I or 124I), X is chosen from O, S, or NH, n is 1-6 (e.g., 1, 2, 3, 4, 5, or 6), the dotted carbon is chiral and is R or S.
C07D 487/22 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes dans le système condensé, non prévus par les groupes dans lesquels le système condensé contient au moins quatre hétérocycles
A nebulizer for medicament is provided. The nebulizer includes a cup having an interior surface. An axle is attached to the cup at least at a location along a central axis of the cup such that rotation of the axle causes a rotation of the cup about the central axis. A fan is operably attached to the axle and configured to generate a flow of air adjacent to the cup. A drum is disposed around a circumference of the cup, and configured to contain the generated flow of air near the cup. A conduit is configured to receive liquid medicament and deposit such medicament on a surface of the cup.
A61M 11/02 - Pulvérisateurs ou vaporisateurs spécialement destinés à des usages médicaux agissant par pression d'air sur les liquides à pulvériser ou vaporiser
The present disclosure relates to a fluid treatment apparatus. The fluid treatment apparatus includes a first system for removing one or more target compounds from a fluid, said first system comprising adsorbent particles; a second system for regenerating said adsorbent particles; a first connector between said first system and said second system, said first connector configured to transfer adsorbent particles from said first system to said second system; and a second connector between said first system and said second system, said second connector configured to release of adsorbent particles from said second system, wherein said first system and said second system are decoupled. The present disclosure further relates to a system comprising one or more fluid treatment apparatus described herein. Also described herein are methods for treating fluid and a system comprising the methods for treating fluid described herein.
B01D 53/02 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par adsorption, p. ex. chromatographie préparatoire en phase gazeuse
B01J 20/04 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant des composés des métaux alcalins, des métaux alcalino-terreux ou du magnésium
56.
COMPOUNDS AND METHODS TO TARGET GLUCOSE-STIMULATED PHOSPHOHISTIDINE SIGNALING AND ESOPHAGEAL CANCER GROWTH
Provided are compounds and compositions that inhibit glucose-induced growth signaling and methods of using same. The compounds may be suitable to treat glycolytic cancers, such as, for example, esophageal squamous cell carcinoma (ESCC). The compounds may be used to inhibit or partially inhibit glucose-promoted tumor cell proliferation, NME-1 catalyzed histidine phosphorylation of FAK, and FAK interaction with RBI. The compounds may have the following structure:
A61K 8/49 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des composés hétérocycliques
C07D 253/065 - Triazines-1, 2, 4 comportant trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques
C07D 253/07 - Triazines-1, 2, 4 comportant trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des hétéro-atomes ou des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
57.
METHODS FOR DISRUPTING MITOCHONDRIAL UNFOLDED PROTEIN RESPONSE
The present disclosure provides methods for treating an individual in need of treatment of conditions in which HSP60/ClpP expression and/or binding is abnormal with a composition having a compound having the following structure: Formula (I) The methods may be used to disrupt mitochondrial unfolded protein response. In various examples, a compound of the composition binds to heat shock protein 60 (HSP60) and inhibits the interaction of HSP60 to ClpP, thus interrupting the mitochondrial unfolded protein response. For example, the composition may be used as a therapeutic approach for treating advanced prostate cancers that are no longer sensitive to AR targeted therapies.
Disclosed herein are novel anti-microbial peptides with inhibitory activity against M. tuberculosis and streptococcus bacteria. Additionally, a method for designing novel anti-microbial peptides is disclosed.
G16B 5/00 - TIC spécialement adaptées à la modélisation ou aux simulations dans la biologie des systèmes, p. ex. réseaux de régulation génétique, réseaux d’interaction entre protéines ou réseaux métaboliques
A01N 43/38 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un atome d'azote comme unique hétéro-atome du cycle des cycles à cinq chaînons condensés avec des carbocycles
A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
59.
EXPLOITING ESTROGEN RECEPTOR BETA AND TP53 INTERACTION AS A NEW THERAPEUTIC STRATEGY FOR CANCER
To induce cancer cell death, cancer cells are selected that express estrogen-receptor β (ERβ) and mutant tumor protein 53 (TP53). An agent that increases ERβ protein expression is administered to the cells to induce cell death. To treat a subject having a cancer that is characterized by cancer cells expressing ERβ and mutant TP53, an agent that increases ERβ protein expression is administered to induce cell death in the cancer cells. To increase estrogen receptor β (ERβ) expression levels in a subject having low ERβ expression levels, tamoxifen is administered to increase ERβ protein levels in the subject. To treat a subject having cancer cells expressing estrogen-receptor β (ERβ) and wildtype tumor protein 53 (TP53), an agent that inhibits ERβ and TP53 binding interaction is administered to induce cell death in the cancer cells of the subject.
An apparatus for identifying and quantifying image distortions within a patient magnetic resonance image set comprises a structure of magnetic resonance compatible materials with a high level of rigidity, where the structure is configured to cover the whole image volume of the brain region of the patient and sized to fit within a brain magnetic resonance coil when worn by a patient. A plurality of magnetic resonance fiducial markers is placed on the structure, thereby permitting the measurement of three-dimensional distances between the markers when the patient undergoes a magnetic resonance imaging procedure. Also presented is a process for identifying and quantifying image distortions within a patient magnetic resonance image set using the apparatus where the geometrical distortion is quantified and compared with a set threshold or a standard image.
Provided are methods for prophylaxis and therapy for viral infections. The methods can facilitate a synergistic anti-viral effect. The method involves administering a combination of agents to an individual in need thereof. The combinations of agents are selected from interferons (IFNs), Toll-Like Receptor (TLR) ligands, polyinosinic:polycytidylic acid, rintatolimod, tumor necrosis factor alpha (TNF-α) or an inducer thereof, and nuclear factor kappa B (NF-ϰB) or an inducer or activator thereof.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
Provided is a method of detecting the presence of an anti-Zika virus (ZIKV) antibody in a sample, including contacting a sample with a suspension having a plurality of microspheres wherein individual microspheres are conjugated to a peptide and the peptide includes a ZIKV peptide selected from the group including ZIKV NS1, ZIKV NS5, and ZIKV envelope protein, forming a first incubated suspension by incubating said sample with said suspension to permit binding of anti-ZIKV antibodies present in the sample to said microspheres, forming a second incubated suspension by contacting said first incubated suspension with an anti-ZIKV antibody detecting-reagent to permit binding of the anti-ZIKV antibody detecting reagent to said microspheres, removing from the second incubated suspension anti-ZIKV antibody detecting-reagent molecules that are not bound to said microspheres, and detecting the presence of anti-ZIKV antibody detecting-reagent molecules in the second incubated suspension. Also provided is a kit containing reagents and compositions for performing the foregoing method.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
63.
METHODS AND COMPOSITIONS FOR TREATING RESISTANT AND RECURRENT FORMS OF CANCER
A method for treating prostate cancer in a subject involves selecting a subject having prostate cancer and cytochrome c-deficiency, and administering, to the selected subject, a therapeutically effective amount of one or more agents capable of restoring cytochrome-c activity. Also presented is a method of inducing apoptosis in drug resistant cancer cells involving selecting drug resistant cancer cells having cytochrome-c deficiency, and administering to the selected cells, one or more agents that restore cytochrome-c activity in an amount effective to sensitize said cancer cells to drug induced apoptosis. A combination therapeutic comprising one or more agents increases cytochrome-c activity and efficacy of a chemotherapeutic agent. Another method involves selecting a subject having cancer, and obtaining a cell sample including tumor tissues/biopsy and blood samples from said subject, and further involves measuring cytochrome-c expression levels and Drp1 phosphorylation levels in said sample.
A61K 31/555 - Composés hétérocycliques contenant des métaux lourds, p. ex. hémine, hématine, mélarsoprol
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61K 31/136 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone ayant le groupe amino lié directement au cycle aromatique, p. ex. benzène-amine
A61K 31/565 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol
A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
A volumetric modulated arc therapy (VMAT) treatment plan may be optimized by obtaining a VMAT treatment plan and calculating a radiation dose matrix corresponding to each a plurality of beamlets, wherein each beamlet represents a change in field when an MLC leaf is moved a predetermined unit distance. The method includes defining an enhanced objective function (EOF) for achieving one or more clinical objectives and minimizing the EOF for proposed leaf positions iterating through each leaf of at least a subset of the leaves of the VMAT treatment plan (wherein the proposed leaf positions move each leaf into the field or out of the field by the predetermined unit distance and correspond to the addition or subtraction of the corresponding radiation dose matrix). The set of leaf positions of the VMAT treatment plan is updated according to the proposed leaf positions of the minimized EOF.
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (USA)
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Li, Hongmin
Li, Zhong
Zhou, Jia
Xu, Jimin
Zhang, Qing-Yu
Abrégé
The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof. The present disclosure further relates to methods of inhibiting viral replication including contacting one or more cells that have been infected with a virus with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the virus comprises a flavivirus. Also disclosed is a method of treating and/or preventing a flavivirus infection and/or a condition resulting from a flavivirus infection including administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof under conditions effective to treat and/or prevent a flavivirus infection and/or a condition resulting from a flavivirus infection.
C07D 265/30 - Oxazines-1, 4Oxazines-1, 4 hydrogénées non condensées avec d'autres cycles
C07C 233/75 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des atomes d'oxygène liés par des liaisons simples avec le radical hydrocarboné substitué lié à l'atome d'azote du groupe carboxamide par un atome de carbone d'un cycle aromatique à six chaînons
C07D 211/46 - Atomes d'oxygène liés en position 4 comportant un atome d'hydrogène comme second substituant en position 4
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C07D 409/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 213/75 - Radicaux amino ou imino, acylés par un acide carboxylique, par l'acide carbonique ou par leurs analogues du soufre ou de l'azote, p. ex. des carbamates
C07D 333/54 - Benzo [b] thiophènesBenzo [b] thiophènes hydrogénés avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone de l'hétérocycle
66.
Compositions and methods for use of recombinant T cell receptors for direct recognition of tumor antigen
+ T cells, natural killer T cells, γδ T cells, and progenitor cells, such as haematopoietic stem cells. The modified cells are capable of direct recognition of a cancer cell expressing a NY-ESO-1 antigen by human leukocyte antigen (HLA) class II-restricted binding of the TCR to the NY-ESO-1 antigen expressed by the cancer cell without presentation of the antigen by antigen presenting cells. In embodiments, the NY-ESO-1 antigen is displayed by the tumor cells. Also included is a method for prophylaxis and/or therapy of cancer by administering modified cells that express a recombinant TCR. Methods for making expression vectors and/or cells which express a recombinant TCR and identifying TCRs to make the expression vectors are also included.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
67.
COMBINATION TREATMENT WITH ANTI-CD123 ANTIBODY DRUG CONJUGATE AND PARP INHIBITOR
A composition including an anti-CD123 antibody-drug conjugate and a poly ADP ribose (PARP) inhibitor can be used in therapy or as a medicament. The composition including the anti-CD123 antibody-drug conjugate and the poly ADP ribose (PARP) inhibitor can be used for treating cancer or for inducing cancer cell death in a population of cancer cells. Hematological cancers such as acute myeloid leukemia (AML) can be treated with the composition. Administering an anti-CD123 antibody-drug conjugate and a poly ADP ribose (PARP) inhibitor is a method of treating cancer. Administering, to a population of cancer cells, an anti-CD123 antibody-drug conjugate and a poly ADP ribose (PARP) inhibitor is a method for inducing cancer cell death.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
A61K 31/5517 - 1,4-Benzodiazépines, p. ex. diazépam condensées avec des cycles à cinq chaînons ayant l'azote comme hétéro-atome d'un cycle, p. ex. imidazobenzodiazépines, triazolam
A61K 31/502 - PyridazinesPyridazines hydrogénées condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. cinnoline, phtalazine
A61K 31/5025 - PyridazinesPyridazines hydrogénées condensées en ortho ou en péri avec des systèmes hétérocycliques
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
68.
COMPOSITIONS, METHODS OF TREATING AND PREVENTING FUNGAL INFECTIONS, AND METHODS OF INHIBITING PRP8 INTEIN EXPRESSION
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (USA)
Inventeur(s)
Li, Hongmin
Li, Zhong
Zhou, Jia
Xu, Jimin
Abrégé
The present disclosure relates to a Prp8 intein splicing inhibitor. The present disclosure further relates to a method of treating and/or preventing a fungal infection, said method comprising administering a Prp8 intein splicing inhibitor under conditions effective to treat and/or prevent a fungal infection. Also disclosed is a method of inhibiting Prp8 intein expression or activity in a cell or tissue, said method comprising administering a compound under conditions effective to inhibit Prp8 intein expression or activity in a cell or tissue. Further disclosed are methods for screening for compounds that inhibit Prp8 intein splicing comprising an assay and a kit for predicting the likelihood of Prp8 inhibition.
A device for automatic suturing includes a shaft having a longitudinal axis. The shaft has a joint rotatable about a joint axis which is at an angle > 0° to the longitudinal axis. The device includes a clamp at a distal end of the shaft. The clamp is configured to be positioned over a length of tissue to be sutured. A driver is configured to engage with a screw of the shaft so that the driver translates along a length of the shaft when the driver is rotated. A helical needle is connected to the driver such that rotation of the driver causes rotation of the helical needle. In this way, the needle is advanced or retracted over a length of the clamp and over the joint of the shaft.
A61B 17/04 - Instruments, dispositifs ou procédés chirurgicaux pour refermer les plaies ou les maintenir ferméesAccessoires utilisés en liaison avec ces opérations pour la suture des plaiesSupports ou emballages pour aiguilles ou matériaux de suture
A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
A61B 17/03 - Instruments, dispositifs ou procédés chirurgicaux pour refermer les plaies ou les maintenir ferméesAccessoires utilisés en liaison avec ces opérations
A61B 17/06 - AiguillesSupports ou empaquetages pour aiguilles ou matériaux de suture
A61B 17/062 - Dispositifs pour manipuler les aiguilles
Georgia State University Research Foundation, Inc. (USA)
Inventeur(s)
Ionov, Yurij
Srivastava, Pramod
Mandoiu, Ion
Zelikovsky, Alex
Abrégé
Provided are methods for identifying antigens containing amino acid sequences for use in a cancer vaccine. The vaccines and methods of use for prophylaxis and/or therapy of cancer are included. The method involves: i) exposing cancer cells to a chemotherapeutic agent that damages DNA; ii) determining open reading frames encoded by mRNA transcribed from a gene in the cancer cells of i); iii) comparing the open reading frames of the mRNA of i) to open reading frames encoded by mRNA transcribed from the gene in the cancer cells that were not exposed to the chemotherapeutic agent, iv) determining a different open reading frame encoded by the mRNA of i) and an open reading frame of the mRNA of ii), wherein the different open reading frame encoded by the mRNA of i) encodes a contiguous amino acid sequence comprising the sequence of the antigen for use in the cancer vaccine.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
Provided are compositions and methods for prophylaxis and/or therapy of ErbB2-positive cancer. The compositions include pharmaceutical preparations that contain isolated or recombinant or modified peptidase D (PEPD) proteins. The methods include prophylaxis and/or therapy of ErbB2-positive cancer by administering a PEPD to an individual who has or is at risk for developing ErbB2-positive cancer.
Modified eukaryotic cells that contain a DNA sequence comprising a drug inducible Cre-recombinase expression system, a sequence encoding a Cas9 enzyme, and a conditional promoter that becomes operably linked to the sequence encoding the Cas9 enzyme by function of the Cre-recombinase system, are provided. The disclosure further provides compositions comprising the modified cells and methods of administering the modified cells to an individual in need thereof.
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
C12N 15/66 - Méthodes générales pour insérer un gène dans un vecteur pour former un vecteur recombinant, utilisant le clivage et la ligatureUtilisation de linkers non fonctionnels ou d'adaptateurs, p. ex. linkers contenant la séquence pour une endonucléase de restriction
Provided is a method for mapping a neural area involved in speech processing, including applying a plurality of recording electrodes to a surface of a cortex of a human subject, presenting a plurality of auditory stimuli to the subject wherein some of the plurality of stimuli are speech sounds and others of the plurality of auditory stimuli are non-speech sounds, recording brain activity during the presenting of the plurality of auditory stimuli, and identifying one or more brain areas wherein activity changes more after presentation of speech sounds than it does after presentation of non-speech sounds, wherein the human subject does not speak during the presenting and the recording. Also provided is a method for mapping a neural area involved in speech production wherein the human subject does not speak during presenting speech stimuli and recording neural activity.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
A61N 1/32 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents
A61B 5/03 - Mesure de la pression des fluides à l'intérieur du corps autre que la pression du sang, p. ex. de la pression cérébrale
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61N 1/05 - Électrodes à implanter ou à introduire dans le corps, p. ex. électrode cardiaque
G16H 20/70 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mentales, p. ex. la thérapie psychologique ou le training autogène
74.
MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II-EXPRESSING CANCER CELL VACCINE AND METHODS OF USE FOR PRODUCING INTEGRATED IMMUNE RESPONSES
Provided are modified cancer cells that are modified to co-express class II trans-activator (CIITA), and an immuno-stimulatory molecule. The immuno-stimulatory molecule is OX-40-ligand or 4-1BB-Ligand. Methods of making the cells are provided by introducing polynucleotides encoding the CIITA and the immune-stimulatory molecule into cancer cells. Methods of stimulating humoral and cell-mediated immune responses by administering the modified cancer cells, or polynucleotides encoding the CIITA and immune-stimulatory molecules are also provided. These approaches can be used to stimulate an immune response against any of a wide variety of cancer antigens.
A method of inhibiting activity or expression of one or more 3α-oxidoreductase enzymes that share a common catalytic site and convert androstanediol to DHT. The method comprises introducing one or more agents into cells that comprise the one or more 3α-oxidoreductase enzymes, wherein said one or more agents: i) inhibit function of one or more of said enzymes; ii) inhibit translation of mRNA encoding said enzymes; iii) disrupt or delete genes encoding said enzymes; or a combination thereof.
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
76.
COMBINATION OF BETA-ADRENERGIC RECEPTOR ANTAGONISTS AND CHECK POINT INHIBITORS FOR IMPROVED EFFICACY AGAINST CANCER
Provided are methods for prophylaxis and/or therapy of cancer that include administering to an individual in need thereof an effective amount of a β-blocker and an immune checkpoint inhibitor such that growth of cancer in the individual is inhibited. Patients include those diagnosed with or at risk for a wide variety of cancer types. Methods are provided for cancer treatment in individuals who are resistant to checkpoint inhibitor monotherapies. Greater than additive anti-cancer effects may be achieved.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 31/138 - Aryloxyalkylamines, p. ex. propranolol, tamoxifène, phénoxybenzamine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
77.
COMPOSITIONS AND METHODS RELATED TO OVERCOMING INNATE IMMUNE BARRIERS TO CANCER IMMUNOTHERAPY
Provided are methods for identifying and treating individuals who have cancer, and also have immunosuppressive neutrophils. The method of treating includes administering one or more drugs that inhibit formation of immunosuppressive neutrophils. Cancer patients can be identified, and selected for treatment, based on a positive result obtained by exposing a biological sample from the patient to normal neutrophils, and subsequently exposing the neutrophils to T cells, and measuring activation of T the cells. Reduced activation of the T cells relative to a control provides an indication that the individual has the immunosuppressive neutrophils, and is a candidate to receive the drug. The drug administered to the cancer patient functions to inhibit SNARE-dependent exocytosis, or inhibits NADPH oxidase, or inhibits complement signaling. The method further includes administering to the individual an immune checkpoint inhibitor, which may increase the efficacy of the checkpoint inhibitor.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
Provided are methods for treatment of cancer. The method comprises administering to an individual who has cancer a combination of treatment to reduce MDSC burden and immune therapy. For example, an individual may be administered brequinar and an immune checkpoint inhibitor. This disclosure provides a method for redirecting early myeloid precursors away from generating MDSCs thereby reducing MDSC burden.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
Provided are methods and compositions for the treatment of cancer. The methods comprise administering to an individual in need of treatment inhibitors of WHSC1 expression, function or activity in combination with PARP inhibitors or immune based therapy. In an aspect, the present disclosure provides compositions comprising one or more WHSC1 inhibitors and one or more PARP inhibitors, or one or more WHSC1 inhibitors and one or more immune checkpoint inhibitors.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
C40B 30/04 - Procédés de criblage des bibliothèques en mesurant l'aptitude spécifique à se lier à une molécule cible, p. ex. liaison anticorps-antigène, liaison récepteur-ligand
C40B 40/06 - Bibliothèques comprenant des nucléotides ou des polynucléotides ou leurs dérivés
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
80.
REACTIVATING P53 MUTANTS FOR CANCER TREATMENT BY TARGETING PROLIDASE (PEPD)
Provided are methods for prophylaxis or therapy of cancer. The methods are directed to cancers that are characterized by expression of a mutant p53. The mutant p53 may be a loss of function p53 mutant, dominant negative p53 mutant, or a gain of function p53 mutant. The method comprises delivering to cancer cells an agent that can inhibit expression of prolidase (PEPD) or disrupts the association of mutant p53 with PEPD.
Provided are methods and formulations for the treatment of p53-deficient cancers using a combinational drug strategy which enhances DNA damage in p53 deficient cells while not allowing cells to escape cell death by activation of p53-p21 signaling. Wild-type p53 carriers, on the other hand, respond with activation of p53-p21 signaling and cell-cycle arrest, thereby escaping cell death. The methods involve administering to an individual in need of treatment a combination of one or more poly (ADP ribose) polymerase inhibitors (PARPi) and one or more deoxyuridine analogs. Pharmaceutical formulations comprising PARPi and dU analogs are also provided.
A method of treating an inflammatory disease or disorder is disclosed. The method comprises administering to the subject a therapeutically effective amount of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 11-15. The inflammatory disease is not cancer, osteoporosis, rheumatic arthritis, osteoarthritis or angiogenesis-related eye disease.
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A spacer for an inhaler includes a housing defining a chamber. The housing has an ambient port in fluid communication with ambient air, an inhaler port configured for attachment of an inhaler, and an outlet. The spacer further includes a fan for generating a flow of air through the chamber from the ambient port to the outlet. The fan may be powered by way of a spring such that the fan generates the flow of air as stored energy is released from a spring. Embodiments of the spacer may have an actuator for triggering a release of stored energy from the spring thereby actuating the fan. A mask or mouthpiece may be provided at the outlet.
The methods and assays described herein relate to detection, diagnosis, and treatment of aberrant immune system activity (e.g., in bronchial premaglinant lesions), e.g., by detecting the level of expression of certain immune regulators described herein and/or by therapeutically modulating the level of those immune regulators.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G16B 25/10 - Profilage de l’expression de gènes ou de protéinesEstimation ou normalisation de ratio d’expression
Provided are survivin specific antibodies, nucleic acids encoding the antibodies and methods for treating tumors comprising survivin-expressing cells by administration of the antibodies. The antibody compositions were found to be effective in inhibiting the growth of tumors.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
Provided are androstane and dihydrotestosterone compounds functionalized with carbocyclic groups or heterocyclic groups that may be saturated or unsaturated. The compounds may be used in methods of inhibiting cell growth of malignant cells and/or hyperplastic cells and/or treating individuals having diseases associated with malignant cell growth (e.g., cancer, such as, for example, prostate cancer) and/or hyperplastic cell growth and/or molecular imaging of malignant cells and/or hyperplastic cells and/or inducing degradation of a target protein. Also provided are compositions.
C07J 1/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène ou de l'oxygène, non substitués en position 17bêta par un atome de carbone, p. ex. œstrane, androstane
C07J 17/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène, ou de l'oxygène, ayant un hétérocycle contenant de l'oxygène non condensé avec le squelette du cyclopenta[a]hydrophénanthrène
C07J 71/00 - Stéroïdes ayant le squelette du cyclopenta[a]hydrophénanthrène condensé avec un hétérocycle
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Pandey, Ravindra, K.
Dukh, Mykhaylo
Marko, Aimee
Sajjad, Munawwar
Abrégé
Compounds for tumor imaging (e.g., magnetic resonance (MR) and fluorescence) that may be used in combination with other methods to treat an individual having or suspected of having cancer (e.g., various forms of cancer, such as, for example, solid tumors). Compounds may have the following structure: (I) or a salt, a partial salt, a hydrate, a polymorph, an isomer (e.g., a structural or stereoisomer), or a mixture thereof, where R' is an aryl group or heteroaryl group having a halogen group (e.g., I or 124I), X is chosen from O, S, or NH, n is 1-6 (e.g., 1, 2, 3, 4, 5, or 6), the dotted carbon is chiral and is R or S.
A61K 31/409 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil ayant quatre de ces cycles, p. ex. dérivés de la porphine, bilirubine, biliverdine
A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
C07D 487/00 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes dans le système condensé, non prévus par les groupes
C07D 487/22 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes dans le système condensé, non prévus par les groupes dans lesquels le système condensé contient au moins quatre hétérocycles
89.
MEDICINAL NEBULIZER AND METHOD OF DISPENSING MEDICAMENT
A nebulizer for medicament is provided. The nebulizer includes a cup having an interior surface. An axle is attached to the cup at least at a location along a central axis of the cup such that rotation of the axle causes a rotation of the cup about the central axis. A fan is operably attached to the axle and configured to generate a flow of air adjacent to the cup. A drum is disposed around a circumference of the cup, and configured to contain the generated flow of air near the cup. A conduit is configured to receive liquid medicament and deposit such medicament on a surface of the cup.
The present disclosure may be embodied as an incontinence device for a catheterized individual. The device includes an absorbent pad configured to be worn by the individual. The absorbent pad having a slit partially separating the pad into two portions. A fastener may be provided for selectively attaching the two portions to each other. In this way, a catheter may be disposed through the slit of the device and the two portions may be attached to each other using the fastener to surround a circumference of the catheter. The fastener may be reusable. In some embodiments, the device includes more than one fastener. The fastener may be one or more of an adhesive, a hook-and-loop fastener, a snap fastener, or combinations thereof.
A61F 13/471 - Serviettes hygiéniques, garnitures ou couches pour incontinence spécialement adaptées pour un usage masculin
A61F 13/62 - Bandes de fixation en matériau textile, p. ex. à crochets et à boucles
A61F 13/78 - Vêtements, dispositifs de soutien ou de support dont les garnitures absorbantes ne forment pas partie intégrante comprenant des moyens pour retenir les garnitures absorbantes disposés perpendiculairement à la largeur des garnitures ou à celle de leurs éléments de fixation, p. ex. lanières, pattes d'extrémité ou replis comportant des boutons ou des boutons-pression
A61F 13/56 - Moyens pour les maintenir en place ou les fixer
91.
IN VIVO MAGNETIC RESONANCE IMAGE DISTORTION CHECK APPARATUS AND METHOD
An apparatus for identifying and quantifying image distortions within a patient magnetic resonance image set comprises a structure of magnetic resonance compatible materials with a high level of rigidity, where the structure is configured to cover the whole image volume of the brain region of the patient and sized to fit within a brain magnetic resonance coil when worn by a patient. A plurality of magnetic resonance fiducial markers is placed on the structure, thereby permitting the measurement of three-dimensional distances between the markers when the patient undergoes a magnetic resonance imaging procedure. Also presented is a process for identifying and quantifying image distortions within a patient magnetic resonance image set using the apparatus where the geometrical distortion is quantified and compared with a set threshold or a standard image.
G06T 7/32 - Détermination des paramètres de transformation pour l'alignement des images, c.-à-d. recalage des images utilisant des procédés basés sur la corrélation
G06T 7/33 - Détermination des paramètres de transformation pour l'alignement des images, c.-à-d. recalage des images utilisant des procédés basés sur les caractéristiques
G06T 7/35 - Détermination des paramètres de transformation pour l'alignement des images, c.-à-d. recalage des images utilisant des procédés statistiques
G06T 7/37 - Détermination des paramètres de transformation pour l'alignement des images, c.-à-d. recalage des images utilisant des procédés de transformation de domaine
A61N 5/02 - Thérapie par radiations utilisant des hyperfréquences
A61N 5/04 - Émetteurs de radiation pour traitement rapproché
A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules
92.
METHODS AND COMPOSITIONS FOR TREATING RESISTANT AND RECURRENT FORMS OF CANCER
A method for treating prostate cancer in a subject involves selecting a subject having prostate cancer and cytochrome c-deficiency, and administering, to the selected subject, a therapeutically effective amount of one or more agents capable of restoring cytochrome-c activity. Also presented is a method of inducing apoptosis in drug resistant cancer cells involving selecting drug resistant cancer cells having cytochrome-c deficiency, and administering to the selected cells, one or more agents that restore cytochrome-c activity in an amount effective to sensitize said cancer cells to drug induced apoptosis. A combination therapeutic comprising one or more agents increases cytochrome-c activity and efficacy of a chemotherapeutic agent. Another method involves selecting a subject having cancer, and obtaining a cell sample including tumor tissues/biopsy and blood samples from said subject, and further involves measuring cytochrome-c expression levels and Drp1 phosphorylation levels in said sample.
To induce cancer cell death, cancer cells are selected that express estrogen-receptor β (ERβ) and mutant tumor protein 53 (TP53). An agent that increases ERβ protein expression is administered to the cells to induce cell death. To treat a subject having a cancer that is characterized by cancer cells expressing ERβ and mutant TP53, an agent that increases ERβ protein expression is administered to induce cell death in the cancer cells. To increase estrogen receptor β (ERβ) expression levels in a subject having low ERβ expression levels, tamoxifen is administered to increase ERβ protein levels in the subject. To treat a subject having cancer cells expressing estrogen-receptor β (ERβ) and wildtype tumor protein 53 (TP53), an agent that inhibits ERβ and TP53 binding interaction is administered to induce cell death in the cancer cells of the subject.
A61K 31/138 - Aryloxyalkylamines, p. ex. propranolol, tamoxifène, phénoxybenzamine
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
94.
COMBINATION TREATMENT WITH ANTI-CD123 ANTIBODY DRUG CONJUGATE AND PARP INHIBITOR
A composition comprising an anti-CD123 antibody-drug conjugate and a poly ADP ribose (PARP) inhibitor can be used in therapy or as a medicament. The composition comprising the anti-CD123 antibody-drug conjugate and the poly ADP ribose (PARP) inhibitor can be used for treating cancer or for inducing cancer cell death in a population of cancer cells. Hematological cancers such as acute myeloid leukemia (AML) can be treated with the composition. Methods for treating cancer comprise administering to a subject an anti-CD123 antibody-drug conjugate and a poly ADP ribose (PARP) inhibitor. Methods for inducing cancer cell death comprise administering, to a population of cancer cells, an anti-CD123 antibody-drug conjugate and a poly ADP ribose (PARP) inhibitor.
GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Ionov, Yurij
Srivastava, Pramod
Mandoiu, Ion
Zelikovsky, Alex
Abrégé
Provided are methods for identifying antigens containing amino acid sequences for use in a cancer vaccine. The vaccines and methods of use for prophylaxis and/or therapy of cancer are included. The method involves: i) exposing cancer cells to a chemotherapeutic agent that damages DNA; ii) determining open reading frames encoded by mRNA transcribed from a gene in the cancer cells of i); iii) comparing the open reading frames of the mRNA of i) to open reading frames encoded by mRNA transcribed from the gene in the cancer cells that were not exposed to the chemotherapeutic agent, iv) determining a different open reading frame encoded by the mRNA of i) and an open reading frame of the mRNA of ii), wherein the different open reading frame encoded by the mRNA of i) encodes a contiguous amino acid sequence comprising the sequence of the antigen for use in the cancer vaccine.
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
A method includes engaging a clamp over a length of tissue to be sutured. A helical needle is advanced along a length of the clamp such that the helical needle passes through the tissue to be sutured. A leading end of a suturing thread is attached at a tip of the helical needle. The leading end of the suturing thread is captured. The helical needle is retracted back through the tissue so as to leave the thread in place. The clamp is disengaged from the tissue. A device for automatic suturing includes a clamp configured to be positioned over a length of tissues to be sutured. A helical needle is configured to be advanced and retracted along a length of the clamp. The needle has a tip. A suturing thread having a leading end is attached to the tip of the helical needle.
A61B 17/04 - Instruments, dispositifs ou procédés chirurgicaux pour refermer les plaies ou les maintenir ferméesAccessoires utilisés en liaison avec ces opérations pour la suture des plaiesSupports ou emballages pour aiguilles ou matériaux de suture
A61B 17/062 - Dispositifs pour manipuler les aiguilles
A61B 17/29 - Pinces pour la chirurgie faiblement invasive
The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents (such as tyrosine kinase inhibitors or VEGF/VEGFR inhibitors), particularly anticancer agents such as sunitinib, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
A61K 31/4412 - Pyridines non condenséesLeurs dérivés hydrogénés ayant des groupes oxo liés directement à l'hétérocycle
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
Linear accelerator (“linac”) downtime invariably impacts delivery of patients' scheduled treatments. Transferring a patient's treatment to an available linac is a common practice. Transferring a VMAT plan from a linac equipped with a standard-definition MLC to one equipped with a higher definition MLC is practical and routine in clinics with multiple MLC-equipped linacs. However, the reverse transfer presents a challenge because the high-definition MLC aperture shapes must be adapted for delivery with the lower definition device. An efficient method to adapt VMAT plans originally designed for a high-definition MLC to a standard definition MLC is disclosed herein. The dosimetric results of the present adaptation method are presented for head-and-neck, brain, lung and prostate VMAT plans. The delivery of the adapted plans was verified using standard phantom measurements.
Compounds including a tetrapyrrolic or reduced tetrapyrrolic group/moiety and an epidermal growth factor receptor targeting group are disclosed. For example, a compound includes a tetrapyrrolic or reduced tetrapyrrolic group or moiety, a linker moiety, an epidermal growth factor receptor targeting group, and, optionally, a PET-active functional group. Uses of the compounds, for example, methods of treating a hyperproliferative tissue in an individual, and kits including one or more of the compounds are also provided.
C07D 487/22 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes dans le système condensé, non prévus par les groupes dans lesquels le système condensé contient au moins quatre hétérocycles
100.
METHODS RELATED TO BRONCHIAL PREMALIGNANT LESION SEVERITY AND PROGRESSION
The technology described herein is directed to methods of treating and diagnosing bronchial premalignant lesions, e.g. by determining the lesion subtype using one or more biomarkers described herein.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
